AndhraNews.net
Home » Features » Health » Pancreatic cancer

Pancreatic cancer


About Pancreatic cancer

Pancreatic cancer is a type of cancer. Amongst popular celebrities who lost fighting pancreatic cancer are actor Patrick Swayze.

Pancreatic cancer in News

Curb Energy Consumption
(Family Features) Water heaters are energy intensive appliances. In fact, they are the second largest energy user in the home, and as they age, they become less efficient, requiring even more energy.

Sunshine Biopharma Acquires All Remaining Worldwide Patents for Its Adva-27a Anticancer Compound
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, announced today that it has acquired all of the remaining rights, title and interest in and to all worldwide patents for the Company's Adva-27a anticancer compound

Basilea provides clinical program updates
Basilea Pharmaceutica AG /Basilea provides clinical program updates. Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Cellceutix Stockholders Tour Company Facilities at First Annual Stockholder Meeting; Investors Express Support for Company and Disgust for Seeking Alpha Article

Cellceutix First Annual Shareholder Meeting December 15, 2015
BEVERLY, MA--(Marketwired - December 14, 2015) - Cellceutix Corporation (OTC: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, today reminds shareholders that tomorrow is the first annual Cellceutix shareholder meeting

MD Anderson's Moon Shots Mission Grows to Confront Six More Cancer Types
HOUSTON, TX--(Marketwired - October 30, 2015) - MD Anderson's Moon Shots Program, an unprecedented effort and novel organizational model designed to more rapidly convert scientific discoveries into life-saving advances, has expanded its targets, adding several of the most intractable cancers to its campaign.

Eric Lefkofksy -- Entrepreneur and Wife Liz Donate $1.2 Million to University of Michigan for Medical Research
CHICAGO, IL--(Marketwired - October 16, 2015) - Eric Lefkofsky, CEO and Co-founder of Groupon, and his wife Liz have pledged $1.2 million to the University of Michigan Health System to further the development of cancer and heart disease research

PharmaCyte Biotech Aims for Consolidated Therapy to Address Unmet Medical Need in Upcoming Cancer Clinical Trial

Sunshine Biopharma Acquires the US Patent for Its Anticancer Compound, Adva-27a
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, announced today that it has acquired all of the right, title and interest in and to U.S. Patent Number 8,236,935 for the Company's Adva-27a anticancer compound

Cellceutix Alerts Shareholders to National Media on Anti-Cancer Abilities of p53
BEVERLY, MA--(Marketwired - October 09, 2015) - Cellceutix Corporation (OTC: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology and antimicrobial applications, today would like to highlight recent national media articles focused on p53 and the potential of the protein's key tumor-suppressing role in controlling cancer.

Armed With FDA Orphan Drug Status in the U.S., PharmaCyte Biotech Now Securing Europe for Pancreatic Cancer Treatment
BONITA, CA--(Marketwired - October 09, 2015) - The combination of PharmaCyte Biotech’s (OTCQB: PMCB) signature live-cell encapsulation technology, Cell-in-a-Box® with low doses of ifosfamide has already won the FDA's "Orphan Drug" status here in the U.S

Scott Kellen Appointed Chief Financial Officer of Sun BioPharma
Sun BioPharma, Inc. (OTC PINK: SNBP), a biopharmaceutical company developing therapies for the treatment of pancreatic diseases, today announced the appointment of Scott Kellen as Vice President of Finance and Chief Financial Officer, effective immediately. Mr

PharmaCyte Biotech Moves Closer to Revealing Plan to Address Unmet Medical Need in Phase 2b Clinical Trial
BONITA, CA--(Marketwired - September 30, 2015) - Cancer is the world's second most common cause of death, not too far behind heart disease. And, although no form of cancer is "good," pancreatic cancer is perhaps the least treatable and most discouraging, taking the lives of more than 86% of its victims within five years of being diagnosed. PharmaCyte Biotech Inc

J. Robert Paulson and Jeffrey Mathiesen Appointed to Sun BioPharma Board of Directors
Sun BioPharma, Inc., (OTC PINK: SNBP), a biopharmaceutical company developing therapies for pancreatic diseases, today announced the appointment of healthcare executives J. Robert Paulson and Jeffrey Mathiesen to the Company's Board of Directors. The appointments are effective immediately and bring the number of directors to 8 members, of which 4 are independent.

David Kaysen Named President & CEO of Sun BioPharma
Sun BioPharma, Inc., (OTC PINK: SNBP), a biopharmaceutical company developing therapies for the treatment of pancreatic cancer, today announced that David B. Kaysen, a veteran healthcare executive, has been appointed President and Chief Executive Officer as well as a member of the Company's Board of Directors effective immediately. Mr

Sun BioPharma Adopts OTCPink Symbol SNBP
Sun BioPharma, Inc. (OTC PINK: SNBP), with its primary focus as a biopharmaceutical company developing therapies for the treatment of pancreatic cancer, is quoted on the OTCPink market under the symbol SNBP. The Company's lead development candidate SBP-101 is expected to begin a Phase 1 clinical trial by the end of the year.

Cellceutix's Clinical Trial of Anti-Cancer Agent Kevetrin Meeting Its Goals, Approaching End of Trial
BEVERLY, MA--(Marketwired - August 20, 2015) - Cellceutix Corporation (OTC: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, today discussed the Phase 1 clinical trial of Kevetrin in patients with advanced solid tumors

PharmaCyte Biotech Has Only Scratched the Surface With Its Cell-in-a-Box(R) Technology
BONITA, CA--(Marketwired - August 17, 2015) - PharmaCyte Biotech Inc. (OTCQB: PMCB) has made a name for itself with the company’s potentially game-changing pancreatic cancer treatment, and also as the name behind what could arguably be seen as a cure for type 1 diabetes

Sunshine Biopharma Announces That the Initial Manufacturing Sample of Its Anticancer Compound Adva-27a Meets Biological Specifications Paving the Way for Clinical Trials
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, announced today that it has completed analysis of the initial Adva-27a manufacturing sample received in June

Boehringer Ingelheim and MD Anderson Cancer Center join forces to discover new treatment approaches for pancreatic cancer
Business Wire IndiaBoehringer Ingelheim and The University of Texas MD Anderson Cancer Center announced a collaboration focused on developing innovative medicines for pancreatic ductal adenocarcinoma (PDAC)

Sunshine Biopharma's Wholly Owned Canadian Subsidiary Completes the SOP's Required by Health Canada to Secure Drug Establishment License
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that its wholly owned Canadian subsidiary has completed the drafting of all of the Standard Operating Procedures (SOP's) required by Health Canada for the procurement of a Drug Establishment License (DEL)

iBio Provides Updates on Its IBIO-CFB03 Fibrosis Drug Candidate and Other Activities for the 2014 Annual Shareholders Meeting
iBio, Inc

Sunshine Biopharma Signs Agreement With Lonza to Manufacture Its Lead Anti-Cancer Compound, Adva-27a
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, announced today an agreement with Lonza, a leading development and manufacturing company, for the manufacture of its anti-cancer drug, Adva-27a

Nuvilex, Inc. Engaged in "Cutting Edge" Cannabis Preclinical Studies Using Model Compounds With Cell-in-a-Box
NEW YORK, NY--(Marketwired - October 29, 2014) -  Nuvilex, Inc. (OTCQB: NVLX) isn't letting the upcoming mid-term elections or the views in Washington, D.C., on medical marijuana slow down its research

Nuvilex, Inc. Moves Closer to "Bio-Artificial Pancreas" Diabetes Treatment With License for Insulin-Producing Cells
NEW YORK, NY--(Marketwired - October 21, 2014) - Nuvilex, Inc. (OTCQB: NVLX) has carefully mapped out its plan to develop a diabetes treatment using the Cell-in-a-Box® platform technology. It started in November 2013 when the company acquired the exclusive worldwide rights to use the cellulose-based live-cell encapsulation technology for the development of treatments for diabetes

Boys & Girls Clubs of Greater Dallas Announces Officers for Its Board of Directors
The Boys & Girls Clubs of Greater Dallas (BGCD) has announced its officers for its board of directors for 2014-2015, its 50th year of working to fulfill its mission of enabling all young people -- especially those who need it most -- to reach their full potential as productive, caring and responsible citizens.

Nuvilex's Cancer Treatment Obtaining FDA Orphan Drug Status Would Make Company Attractive Big Pharma Target
NEW YORK, NY--(Marketwired - October 14, 2014) - Nuvilex, Inc. (OTCQB: NVLX) has officially introduced its advanced pancreatic cancer treatment to the U.S. Food and Drug Administration (FDA) in an application asking the agency to grant orphan drug status to its Cell-in-a-Box®/ifosfamide combination for the rare disease.

Sunshine Biopharma Retains Renmark Financial Communications to Provide Investor Relations
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, including its proprietary lead anticancer compound Adva-27a, today announced that it has retained the services of Renmark Financial Communications Inc. to handle its investor relations activities.

PharmaEngine will join Nanobiotix' pivotal trial for NBTXR3 in Soft Tissue Sarcoma to accelerate its development in Asia-Pacific
 

immixGroup Foundation Tenth Annual Charity Golf Tournament Raises $125,000 for Cancer Research
MCLEAN, VA--(Marketwired - October 03, 2014) - The immixGroup Foundation announced today it has raised $125,000 to support cancer research, education, and patient care at Johns Hopkins. The foundation is a non-profit 501(c)(3) organization affiliated with immixGroup, Inc. immixGroup helps technology companies do business with the government.

Novartis drug Afinitor is first treatment for advanced pancreatic NET to provide overall survival of more than 3.5 years in Phase III trial
Novartis International AG /Novartis drug Afinitor is first treatment for advanced pancreatic NET to provide overall survival of more than 3.5 years in Phase III trial . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Chemotherapy and Stereotactic Ablative Radiation Consecutively May Be Promising Treatment Option for Patients With Advanced Pancreatic Cancer

Sunshine Biopharma Negotiating With CRO's to Initiate Master Drug File for Adva-27a Anticancer Compound
Sunshine Biopharma Inc

Dr. Thomas A. Medsger Jr. Joins iBio Clinical Advisory Board
iBio, Inc. (NYSE MKT: IBIO), a leading provider of biotechnology for developing and manufacturing plant-made pharmaceutical products, has appointed Thomas A. Medsger Jr., M.D., to its clinical advisory board.

NewLink Genetics Corporation, Through Its Wholly Owned Subsidiary, BioProtection Systems Corporation, Secures a Letter Contract From the Defense Threat Reduction Agency for Testing and Evaluation of Ebola Virus Vaccine
NewLink Genetics Corporation (NASDAQ: NLNK), through its wholly owned subsidiary, BioProtection Systems Corporation (BPS), today announced a letter contract with the United States Defense Threat Reduction Agency (DTRA) for studies that will bring an Ebola vaccine licensed from the Public Health Agency of Canada closer to human clinical trials. The letter contract is for $1

NewLink Genetics Corporation Reports Second Quarter 2014 Financial Results
NewLink Genetics Corporation (NASDAQ: NLNK) today reported consolidated financial results for the second quarter of 2014 and progress in its development programs.

iBio Appoints Another IPF Expert, Dr. J. Terrill Huggins, to Clinical Advisory Board
iBio, Inc. (NYSE MKT: IBIO), a leading provider of plant-based biotechnology for developing and manufacturing biological products, has appointed J. Terrill Huggins, M.D. to its clinical advisory board. The board of science and medical experts is assisting iBio in its clinical and product strategy.

Sunshine Biopharma Launches Sunshine Biopharma Canada Inc., a Wholly Owned Canadian Subsidiary in Anticipation of Signing Manufacturing and Commercialization Contracts in Canada
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has formed Sunshine Biopharma Canada Inc., a Canadian wholly owned subsidiary for the purposes of conducting pharmaceutical business in Canada and elsewhere around the globe

Global Survey Finds That Pancreatic Cancer, a Leading Cause of Cancer Deaths, is Virtually Unknown by Many in Europe and US
While it may not be surprising that breast and lung cancers are top of mind when people hear the word “cancer,” 60% of respondents to a recent six-country survey about cancer awareness know almost nothing about pancreatic cancer, a leading cancer killer

Provectus Signs Memorandum of Understanding with Sinopharm-China State Institute of Pharmaceutical Industry, and Sinopharm A-THINK Pharmaceutical Co., Ltd.
Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT) (http://www.pvct

NewLink Genetics Launches Phase 1 Clinical Trial of Its HyperAcute(TM) Renal Immunotherapy in Patients With Metastatic Renal Cell Cancer
NewLink Genetics Corporation (NASDAQ: NLNK), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that it had launched a first in human Phase 1 clinical trial of HyperAcute Renal immunotherapy in patients with metastatic renal cell cancer

Nuvilex's Medical Marijuana Research Could Use Cell Encapsulation Technology to Address Brain Cancers
The executives at Nuvilex, Inc. (OTCQB: NVLX) and its subsidiary, Medical Marijuana Sciences, Inc., had to take note of recent results released in a marijuana study done by a group of researchers in Spain. The study used a type of encapsulation to inhibit brain cancer cell growth in mice

Nuvilex to Answer Increasing Calls for Better Pancreatic Cancer Treatment Without Gemcitabine
Nuvilex, Inc. (OTCQB: NVLX) may be just what the National Cancer Institute (NCI) and a growing number of doctors ordered - the company's late stage clinical trials in advanced, inoperable pancreatic cancer that is

Phase II Data on OHR/AVR118 in Advanced Cancer Patients With Cachexia Presented at International Cachexia Conference in Kobe, Japan
Ohr Pharmaceutical (NASDAQ: OHRP), a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, announced that full results from a Phase II trial to evaluate the effects of OHR/AVR118 in advanced cancer patients with cachexia were presented yesterday at the 7th International Cachexia Conference in Kobe, Japan

Childress Engineering Services Is "Going the Distance" -- Raises Nearly $40,000 and Runs More Than 200 Miles
Over the past few months Childress Engineering Services, Inc. has continued its mission to help others improve their quality of life through sponsorship opportunities and participation in a series of charitable events where donations can help fund awareness and fund research for a cure.

NewLink Genetics Initiates Phase 1 Clinical Trial of NLG919, a Novel Immune Checkpoint Inhibitor for Cancer Immunotherapy
NewLink Genetics Corporation (NASDAQ: NLNK), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced the initiation of a first in human Phase 1 clinical trial of NLG919. This is NewLink's second IDO (indoleamine-(2,3)-dioxygenase) pathway inhibitor that will initially be tested in patients with recurrent advanced solid tumors

Latteno's Co-Op Valley Organics Introduces New Medical Cannabis Products
Latteno Food Corp.'s (OTC Pink: LATF) wholly-owned subsidiary Co-op Valley Organics, today announced CBD-100, a 100% Organics, 100% Natural Hemp Oil for Medical Cannabis patients. This is an exclusive right to market and distribute with defined term and conditions. Our CBD-100 is made from Canadian Industrial Hemp NOT from Marijuana

After Pancreatic Cancer, Eli Lilly and Nuvilex Could Battle Over Diabetes Treatment
Eli Lilly & Co. (LLY) has parlayed its cancer drug Gemzar® or gemcitabine into well over $10 billion since it gained approval to treat advanced, inoperable pancreatic cancer back in 1996. Meanwhile, Nuvilex, Inc. (OTCQB: NVLX) has its eyes on a piece of that billion dollar pie with the company's live-cell encapsulation based treatment for pancreatic cancer

Sunshine Biopharma to Re-Domicile in Canada for Expansion and Financing Opportunities for Adva-27a Cancer Drug Candidate
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it is re-domiciling the Company in Canada for expansion through acquisitions and to gain access to various financing opportunities available to Canadian corporations

Nuvilex's Acquisition of Diabetes Rights Should Put the Company on Everyone's Radar
Nuvilex, Inc. (OTCQB: NVLX) recently acquired the exclusive worldwide rights to a proprietary cellulose-based live-cell encapsulation technology for developing treatments for all types of cancer, most notably pancreatic cancer

Nuvilex: The Triple Threat
In a newly released article, Goldman Small Cap Research, a stock market research firm focused on the small cap and micro cap sectors, notes that with a presence in disparate but potentially related markets, Nuvilex, Inc. (OTCQB: NVLX) is a triple threat that offers investors huge potential

NewLink Genetics Corporation Reports Third Quarter 2013 Financial Results
NewLink Genetics Corporation (NASDAQ: NLNK)

Prima BioMed Updates CVac Development Program; Clinical Trial Focus on Second-Remission Ovarian Cancer Patient Population
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (ISIN: US74154B2034) ("Prima", the "Company"), in its most recent quarterly call, provided significant updates to its CVac™ clinical development program.

Pair of 2014 "Linda Vaughn LV-1" Camaros Designed by Doc Watson Unveiled at Barrett-Jackson Display at 2013 SEMA Show
A pair of custom, 2014 "Linda Vaughn LV-1" Chevrolet Camaros designed by legendary vehicle developer Jack "Doc" Watson, the creator of the first Hurst/Olds in 1968, were unveiled Wednesday, live from the Barrett-Jackson display at the 2013 SEMA Show.

Nuvilex Announces Cloning of Cells for Future Phase 3 Clinical Trials Initiated by Inno Biologics
Nuvilex, Inc. (OTCQB: NVLX), an international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that cloning of the cancer-drug-activating cells required for Nuvilex's future Phase 3 clinical trials has begun at Inno Biologics in its cGMP-compliant facilities.

Is Nuvilex Ready to Acquire Diabetes Technology and Control Cancer and Diabetes Cell Encapsulation Markets?
With October behind us, Nuvilex, Inc. (OTCQB: NVLX) investors should see a new acquisition this month. Two weeks ago Stock Market Media Group, a research and content development investor relations firm, released an audio interview with Nuvilex's COO, Dr

Traders Eyeing Near-Term Upside in Nuvilex's Shares
In a newly released article, Goldman Small Cap Research, a stock market research firm focused on the small cap and micro cap sectors, notes that savvy traders and followers of Nuvilex, Inc. (OTCQB: NVLX) can sense that a return to much higher levels is brewing. For starters, the Company's shares have reached a key pivot point at current levels and have strong support at the $0.112/$0.113 mark

Nuvilex, Inc.: Anatomy of a Biotech
In a newly released article, Goldman Small Cap Research, a stock market research firm focused on the small cap and micro cap sectors, notes that a series of upcoming milestone news events appear to be catalysts that should move the shares of Nuvilex, Inc. (OTCQB: NVLX) substantially higher, prior to the seasonal biotech surge.

BB Biotech continues its strong performance - third-quarter profit CHF 338.8 mn / share price up more than 50% since beginning of the year
BB BIOTECH AG /BB Biotech continues its strong performance - third-quarter profit CHF 338.8 mn / share price up more than 50% since beginning of the year . Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

ABRAXANE® Phase III Study of Patients with Metastatic Pancreatic Cancer Published in New England Journal of Medicine

Peregrine Pharmaceuticals Reports Second Quarter Fiscal Year 2013 Financial Results and Recent Developments
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced financial results for the second quarter ended October 31, 2012 of fiscal year (FY) 2013 and provided an update on its advancing clinical pipeline and other corporate developments.

Propanc Issues Summary of Recent Achievements
Propanc Health Group Corporation (OTCQB: PPCH) ("Propanc" or "the Company"), a developmental stage healthcare company focused on new cancer treatments for patients with solid tumors, issued a summary of recent achievements that position the company for planned future growth in the next twelve months.

Coare Biotechnology and ChemDiv Establish Co-Marketing and Service Collaboration
COARE Biotechnology (COARE) and ChemDiv, Inc. (ChemDiv) announced today the formation of a strategic alliance that will offer a fully integrated gene-to-clinic services aimed at development of therapeutic agents that selectively affect cancer stem cells (CSC).

MorphoSys AG Reports Nine Months 2012 Results
MorphoSys AG /MorphoSys AG Reports Nine Months 2012 Results. Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

New Data Support Ability of PS-Targeting Antibodies to Specifically Target Tumors and Stimulate Cancer-Fighting Immune Responses
Peregrine Pharmaceuticals (NASDAQ: PPHM), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced the presentation of preclinical data showing specific localization and enhancement of anti-tumor functions of immune cells inside tumors following administration of phosphatidylserine (PS)-targeting antibodies

NewLink Genetics Corporation Reports Third Quarter 2012 Financial Results
NewLink Genetics Corporation (NASDAQ: NLNK), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today reported consolidated financial results for the third quarter of 2012

Petra Rietschel, MD: Breast Cancer Treatment May Prove Beneficial in Melanoma Cases
Cancer treatments have evolved a great deal over the last few decades, and many of today's researchers are focusing on ways in which they can combine and cross-prescribe these drugs to effectively combat a variety of conditions

PropThink: Abraxane Data, Earnings Release Rally CELG; Back to Highs by Year End?
By Jake KingIn separate press releases on Thursday morning, Celgene (NASDAQ:CELG) reported 3Q results and announced that Abraxane demonstrated a statistically significant improvement in Progression Free Survival (PFS) in its latest Phase 3 study for advanced melanoma. Celgene reported revenue of $1.42B and adjusted, diluted earnings of $1

Mauna Kea Technologies Announces New Data Supporting Clinical Utility of Cellvizio(R)

Peregrine Pharmaceuticals Provides Update on Corporate Activities
Peregrine Pharmaceuticals (NASDAQ: PPHM), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today provided a company update on financing activities, its contract manufacturing business and upcoming potential clinical milestones.

MorphoSys's Partner OncoMed Advances the HuCAL Antibody OMP-59R5 into Phase 1b/2 Clinical Trial in Pancreatic Cancer
MorphoSys AG /MorphoSys's Partner OncoMed Advances the HuCAL Antibody OMP-59R5 into Phase1b/2Clinical Trial in Pancreatic Cancer Processed and transmitted by ThomsonReuters ONE.The issuer is solely responsible for the content of this announcement.

MorphoSys's Partner OncoMed Advances the HuCAL Antibody OMP-59R5 into Phase 1b/2 Clinical Trial in Pancreatic Cancer
MorphoSys AG /MorphoSys's Partner OncoMed Advances the HuCAL Antibody OMP-59R5 into Phase 1b/2 Clinical Trial in Pancreatic Cancer . Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

PropThink: Celgene Nearing 52-week High on Abraxane Data, Upcoming PDUFA
By Jake KingCelgene (NASDAQ:CELG) moved closer today to securing another indication for its oncology drug, Abraxane, which is already approved as a second-line treatment for metastatic breast cancer

Peregrine Pharmaceuticals Reports First Quarter Fiscal Year 2013 Financial Results and Recent Developments
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced financial results for the first quarter ended July 31, 2012 of fiscal year (FY) 2013 and provided an update on its advancing clinical pipeline and other corporate developments.

Interim Data From Peregrine's Phase II Trial in Second-Line Non-Small Cell Lung Cancer Demonstrate Doubling of Median Overall Survival in Bavitiximab-Containing Arms

Data From Peregrine's Phase II Bavituximab Second-Line Lung Cancer Trial to Be Highlighted in Late-Breaking Oral Presentation at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology
Peregrine Pharmaceuticals, Inc

PropThink: Catalyst in Threshold Pharmaceuticals; Interim Trial Data by Year's-End
Since reporting 2Q earnings on August 2nd, Threshold Pharmaceuticals (NASDAQ:THLD) gained 25% and is on track to end the month around $8.70, a $.50 premium to Friday's opening price. On Wednesday the company announced upcoming presentations at two investor conferences, Stifel Nicolaus and BioCentury NewsMakers, on the 5th and 7th

Mauna Kea Technologies Announces Full Financial Results for First Half of 2012
Mauna Kea Technologies (EURONEXT PARIS: MKEA)

ABRAXANE® Demonstrates Statistically Significant Improvement in Overall Survival for Patients with Advanced Pancreatic Cancer in Phase III Study

Apple pays tribute to Steve Jobs on his first death anniversary
Apple posted a video of snippets of Steve Jobs on its homepage

Patrick Swayze renewed marriage vows with wife while fighting cancer
Late actor Patrick Swayze and his wife Lisa Niemi had renewed their marriage vows as the actor battled with cancer.

Steve Jobs to receive posthumous Grammy award
Steve Jobs will be posthumously honoured with the 'Trustees Award' at the Grammys next year for his "outstanding contributions to the industry in a non-performing capacity".

Gene that may up risk of hereditary pancreatic cancer identified
Scientists have discovered that mutations in the ATM gene may increase the hereditary risk for pancreatic cancer.

Potential target to delay 'deadliest' cancer and prolong survival identified
Researchers have found a new way to disrupt the process of pancreatic cancer cells and slow down their mobility.

Soon, vaccine that can shrink tumours by 80pc!
Scientists have developed a vaccine that promises a new strategy for treating ovarian, colorectal and pancreatic cancer.

Threshold Pharmaceuticals Announces Promising Phase 1 Clinical Trial Results in Patients With Advanced Leukemias
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced clinical trial results of the Phase 1 study of TH-302 in patients with advanced leukemias conducted at MD Anderson's Cancer Center in Houston, Texas.

Threshold Pharmaceuticals Announces Update to TH-302 Pancreatic Data to Be Presented at the Oppenheimer Healthcare Conference
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Dr. Barry Selick, Threshold's Chief Executive Officer, is scheduled to present an update at the Oppenheimer 22nd Annual Healthcare Conference in New York City on the Company's corporate and clinical development

Peregrine Pharmaceuticals Reports Second Quarter 2012 Financial Results and Recent Developments
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced financial results for the second quarter ended October 31, 2011 of fiscal year (FY) 2012 and provided an update on its advancing clinical pipeline and other corporate developments.

Promising interim results of Phase II trial with elacytarabine in combination with idarubicin in patients with early stage acute myeloid leukaemia (AML) presented at ASH annual meeting
Oslo, Norway

MediGene Presents Overall Survival Data from a Phase II Trial of EndoTAG®-1 in Triple-Negative Breast Cancer (TNBC)
MediGene AG /MediGene Presents Overall Survival Data from a Phase II Trial of EndoTAG®-1 in Triple-Negative Breast Cancer (TNBC) . Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

Comment on this story

Share